News
12-13-2009, 11:41 PM
Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.
More... (http://www.news-medical.net/news/20091214/Genentech-announces-positive-results-from-Phase-II-study-of-T-DM1.aspx)
More... (http://www.news-medical.net/news/20091214/Genentech-announces-positive-results-from-Phase-II-study-of-T-DM1.aspx)